Skip to main content
Top
Published in: Annals of Surgical Oncology 13/2019

01-12-2019 | Sarcoma

Outcome of Primary Desmoid Tumors at All Anatomic Locations Initially Managed with Active Surveillance

Authors: Winan J. van Houdt, MD, PhD, MSc, Olga Husson, PhD, Alisha Patel, Robin L. Jones, MD, Myles J. F. Smith, MB, BCh, BAO, PhD, FRCSI, Aisha B. Miah, MD, PhD, Christina Messiou, MD, Eleonor Moskovic, MD, Omar Al-Muderis, Charlotte Benson, MD, Shane Zaidi, MD PhD, Alison Dunlop, Dirk C. Strauss, MD, Andrew J. Hayes, MD, PhD, Winette T. A. van der Graaf, MD, PhD

Published in: Annals of Surgical Oncology | Issue 13/2019

Login to get access

Abstract

Background

The behavior of desmoid tumors is unpredictable and varies from spontaneous remission to symptomatic and radiologic progression. This study aimed to evaluate the radiologic and symptomatic course of the disease in patients initially managed with active surveillance.

Methods

Patients with a primary desmoid tumor at any anatomic location diagnosed between 1998 and 2016 were identified in a prospectively maintained database from a single sarcoma reference center in the United Kingdom. Inverse univariate Cox proportional hazard regression analyses were conducted to evaluate the course of the disease and indications for initiating treatment.

Results

The study identified 168 patients with a primary desmoid tumor initially managed with active surveillance. The tumors were located in the abdominal wall (n = 61, 36%), an extremity (n = 51, 30%), chest wall (n = 30, 18%), intra-abdominal site (n = 15, 9%), or elsewhere (n = 11, 6%). Of all the patients, 36% experienced radiologic progressive disease, 36% had stable disease, and 27% regressed. The patients younger than 50 years were more likely to progress (p = 0.046), whereas the patients with chest wall or upper-extremity tumors reported significantly more pain (p = 0.01). Eventually, 46% of the patients proceeded to treatment. The median time to start of treatment after initial surveillance was 31 months, whereas the median follow-up time for the patients not receiving any treatment was 40.5 months. The indications for initiation of treatment were pain (32%), progression (31%), or both (13%).

Conclusions

Patients with desmoid tumors can be managed with initial active surveillance, although almost half of patients may eventually need treatment. Pain, tumor progression, or both are the most common indications for the initiation of treatment.
Literature
1.
go back to reference Li M, Cordon-Cardo C, Gerald WL, Rosai J. Desmoid fibromatosis is a clonal process. Hum Pathol. 1996;27:939–43.CrossRef Li M, Cordon-Cardo C, Gerald WL, Rosai J. Desmoid fibromatosis is a clonal process. Hum Pathol. 1996;27:939–43.CrossRef
2.
go back to reference Wu C, Amini-Nik S, Nadesan P, Stanford WL, Alman BA. Aggressive fibromatosis (desmoid tumor) is derived from mesenchymal progenitor cells. Cancer Res. 2010;70:7690–8.CrossRef Wu C, Amini-Nik S, Nadesan P, Stanford WL, Alman BA. Aggressive fibromatosis (desmoid tumor) is derived from mesenchymal progenitor cells. Cancer Res. 2010;70:7690–8.CrossRef
3.
go back to reference de Bree E, Keus R, Melissas J, Tsiftsis D, van Coevorden F. Desmoid tumors: need for an individualized approach. Expert Rev Anticancer Ther. 2009;9:525–35.CrossRef de Bree E, Keus R, Melissas J, Tsiftsis D, van Coevorden F. Desmoid tumors: need for an individualized approach. Expert Rev Anticancer Ther. 2009;9:525–35.CrossRef
4.
go back to reference Crago AM, Denton B, Salas S, Dufresne A, Mezhir JJ, Hameed M, et al. A prognostic nomogram for prediction of recurrence in desmoid fibromatosis. Ann Surg. 2013;258:347–53.CrossRef Crago AM, Denton B, Salas S, Dufresne A, Mezhir JJ, Hameed M, et al. A prognostic nomogram for prediction of recurrence in desmoid fibromatosis. Ann Surg. 2013;258:347–53.CrossRef
5.
go back to reference Reitamo JJ, Scheinin TM, Hayry P. The desmoid syndrome: new aspects in the cause, pathogenesis, and treatment of the desmoid tumor. Am J Surg. 1986;151:230–7.CrossRef Reitamo JJ, Scheinin TM, Hayry P. The desmoid syndrome: new aspects in the cause, pathogenesis, and treatment of the desmoid tumor. Am J Surg. 1986;151:230–7.CrossRef
6.
go back to reference Nieuwenhuis MH, Casparie M, Mathus-Vliegen LM, Dekkers OM, Hogendoorn PC, Vasen HF. A nation-wide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses. Int J Cancer. 2011;129:256–61.CrossRef Nieuwenhuis MH, Casparie M, Mathus-Vliegen LM, Dekkers OM, Hogendoorn PC, Vasen HF. A nation-wide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses. Int J Cancer. 2011;129:256–61.CrossRef
7.
go back to reference Janssen ML, van Broekhoven DL, Cates JM, Bramer WM, Nuyttens JJ, Gronchi A, et al. Meta-analysis of the influence of surgical margin and adjuvant radiotherapy on local recurrence after resection of sporadic desmoid-type fibromatosis. Br J Surg. 2017;104:347–57.CrossRef Janssen ML, van Broekhoven DL, Cates JM, Bramer WM, Nuyttens JJ, Gronchi A, et al. Meta-analysis of the influence of surgical margin and adjuvant radiotherapy on local recurrence after resection of sporadic desmoid-type fibromatosis. Br J Surg. 2017;104:347–57.CrossRef
8.
go back to reference Kasper B, Baumgarten C, Bonvalot S, Haas R, Haller F, Hohenberger P, et al. Management of sporadic desmoid-type fibromatosis: a European consensus approach based on patients’ and professionals’ expertise: a sarcoma patients’ EuroNet and European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group initiative. Eur J Cancer. 2015;51:127–36.CrossRef Kasper B, Baumgarten C, Bonvalot S, Haas R, Haller F, Hohenberger P, et al. Management of sporadic desmoid-type fibromatosis: a European consensus approach based on patients’ and professionals’ expertise: a sarcoma patients’ EuroNet and European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group initiative. Eur J Cancer. 2015;51:127–36.CrossRef
9.
go back to reference Bonvalot S, Desai A, Coppola S, Le Pechoux C, Terrier P, Domont J, et al. The treatment of desmoid tumors: a stepwise clinical approach. Ann Oncol. 2012;23(Suppl 10):x158–66.CrossRef Bonvalot S, Desai A, Coppola S, Le Pechoux C, Terrier P, Domont J, et al. The treatment of desmoid tumors: a stepwise clinical approach. Ann Oncol. 2012;23(Suppl 10):x158–66.CrossRef
10.
go back to reference Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, et al. Sorafenib for advanced and refractory desmoid tumors. N Engl J Med. 2018;379:2417–28.CrossRef Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, et al. Sorafenib for advanced and refractory desmoid tumors. N Engl J Med. 2018;379:2417–28.CrossRef
11.
go back to reference Grunhagen DJ, de Wilt JH, Verhoef C, van Geel AN, Eggermont AM. TNF-based isolated limb perfusion in unresectable extremity desmoid tumours. Eur J Surg Oncol. 2005;31:912–6.CrossRef Grunhagen DJ, de Wilt JH, Verhoef C, van Geel AN, Eggermont AM. TNF-based isolated limb perfusion in unresectable extremity desmoid tumours. Eur J Surg Oncol. 2005;31:912–6.CrossRef
12.
go back to reference Fiore M, Rimareix F, Mariani L, Domont J, Collini P, Le Pechoux C, et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol. 2009;16:2587–93.CrossRef Fiore M, Rimareix F, Mariani L, Domont J, Collini P, Le Pechoux C, et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol. 2009;16:2587–93.CrossRef
13.
go back to reference Colombo C, Miceli R, Le Pechoux C, Palassini E, Honore C, Stacchiotti S, et al. Sporadic extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. Eur J Cancer. 2015;51:186–92.CrossRef Colombo C, Miceli R, Le Pechoux C, Palassini E, Honore C, Stacchiotti S, et al. Sporadic extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. Eur J Cancer. 2015;51:186–92.CrossRef
14.
go back to reference Burtenshaw SM, Cannell AJ, McAlister ED, Siddique S, Kandel R, Blackstein ME, et al. Toward observation as first-line management in abdominal desmoid tumors. Ann Surg Oncol. 2016;23:2212–9.CrossRef Burtenshaw SM, Cannell AJ, McAlister ED, Siddique S, Kandel R, Blackstein ME, et al. Toward observation as first-line management in abdominal desmoid tumors. Ann Surg Oncol. 2016;23:2212–9.CrossRef
15.
go back to reference Kasper B, Baumgarten C, Garcia J, Bonvalot S, Haas R, Haller F, et al. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). Ann Oncol. 2017;28:2399–408.CrossRef Kasper B, Baumgarten C, Garcia J, Bonvalot S, Haas R, Haller F, et al. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). Ann Oncol. 2017;28:2399–408.CrossRef
16.
go back to reference Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
17.
go back to reference Bonvalot S, Ternes N, Fiore M, Bitsakou G, Colombo C, Honore C, et al. Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought. Ann Surg Oncol. 2013;20:4096–102.CrossRef Bonvalot S, Ternes N, Fiore M, Bitsakou G, Colombo C, Honore C, et al. Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought. Ann Surg Oncol. 2013;20:4096–102.CrossRef
18.
go back to reference Penel N, Le Cesne A, Bonvalot S, Giraud A, Bompas E, Rios M, et al. Surgical versus nonsurgical approach in primary desmoid-type fibromatosis patients: a nationwide prospective cohort from the French Sarcoma Group. Eur J Cancer. 2017;83:125–31.CrossRef Penel N, Le Cesne A, Bonvalot S, Giraud A, Bompas E, Rios M, et al. Surgical versus nonsurgical approach in primary desmoid-type fibromatosis patients: a nationwide prospective cohort from the French Sarcoma Group. Eur J Cancer. 2017;83:125–31.CrossRef
19.
go back to reference Fiore M, Colombo C, Radaelli S, Callegaro D, Palassini E, Barisella M, et al. Hormonal manipulation with toremifene in sporadic desmoid-type fibromatosis. Eur J Cancer. 2015;51:2800–7.CrossRef Fiore M, Colombo C, Radaelli S, Callegaro D, Palassini E, Barisella M, et al. Hormonal manipulation with toremifene in sporadic desmoid-type fibromatosis. Eur J Cancer. 2015;51:2800–7.CrossRef
20.
go back to reference Colombo C, Bolshakov S, Hajibashi S, Lopez-Terrada L, Wang WL, Rao P, et al. “Difficult-to-diagnose” desmoid tumours: a potential role for CTNNB1 mutational analysis. Histopathology. 2011;59:336–40.CrossRef Colombo C, Bolshakov S, Hajibashi S, Lopez-Terrada L, Wang WL, Rao P, et al. “Difficult-to-diagnose” desmoid tumours: a potential role for CTNNB1 mutational analysis. Histopathology. 2011;59:336–40.CrossRef
21.
go back to reference Lazar AJ, Tuvin D, Hajibashi S, Habeeb S, Bolshakov S, Mayordomo-Aranda E, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol. 2008;173:1518–27.CrossRef Lazar AJ, Tuvin D, Hajibashi S, Habeeb S, Bolshakov S, Mayordomo-Aranda E, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol. 2008;173:1518–27.CrossRef
22.
go back to reference van Broekhoven DL, Verhoef C, Grunhagen DJ, van Gorp JM, den Bakker MA, Hinrichs JW, et al. Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis. Ann Surg Oncol. 2015;22:1464–70.CrossRef van Broekhoven DL, Verhoef C, Grunhagen DJ, van Gorp JM, den Bakker MA, Hinrichs JW, et al. Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis. Ann Surg Oncol. 2015;22:1464–70.CrossRef
23.
go back to reference Timbergen MJM, van de Poll-Franse LV, Grunhagen DJ, van der Graaf WT, Sleijfer S, Verhoef C, et al. Identification and assessment of health-related quality-of-life issues in patients with sporadic desmoid-type fibromatosis: a literature review and focus group study. Qual Life Res. 2018;27:3097–111.CrossRef Timbergen MJM, van de Poll-Franse LV, Grunhagen DJ, van der Graaf WT, Sleijfer S, Verhoef C, et al. Identification and assessment of health-related quality-of-life issues in patients with sporadic desmoid-type fibromatosis: a literature review and focus group study. Qual Life Res. 2018;27:3097–111.CrossRef
24.
go back to reference Husson O, Younger E, Dunlop A, Dean L, Strauss DC, Benson C, et al. Desmoid fibromatosis through the patients’ eyes: time to change the focus and organisation of care? Support Care Cancer. 2019;27(3):965–80.CrossRef Husson O, Younger E, Dunlop A, Dean L, Strauss DC, Benson C, et al. Desmoid fibromatosis through the patients’ eyes: time to change the focus and organisation of care? Support Care Cancer. 2019;27(3):965–80.CrossRef
25.
go back to reference Rigaux P, Lefebvre-Kuntz D, Penel N, Desmoide SOS. Pain burden in desmoid tumor patients: a survey of the French Advocacy Group SOS Desmoid. Bull Cancer. 2015;102:213–6.CrossRef Rigaux P, Lefebvre-Kuntz D, Penel N, Desmoide SOS. Pain burden in desmoid tumor patients: a survey of the French Advocacy Group SOS Desmoid. Bull Cancer. 2015;102:213–6.CrossRef
26.
go back to reference Libertini M, Mitra I, van der Graaf WTA, Miah AB, Judson I, Jones RL, et al. Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response. Clin Sarcoma Res. 2018;8:13.CrossRef Libertini M, Mitra I, van der Graaf WTA, Miah AB, Judson I, Jones RL, et al. Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response. Clin Sarcoma Res. 2018;8:13.CrossRef
Metadata
Title
Outcome of Primary Desmoid Tumors at All Anatomic Locations Initially Managed with Active Surveillance
Authors
Winan J. van Houdt, MD, PhD, MSc
Olga Husson, PhD
Alisha Patel
Robin L. Jones, MD
Myles J. F. Smith, MB, BCh, BAO, PhD, FRCSI
Aisha B. Miah, MD, PhD
Christina Messiou, MD
Eleonor Moskovic, MD
Omar Al-Muderis
Charlotte Benson, MD
Shane Zaidi, MD PhD
Alison Dunlop
Dirk C. Strauss, MD
Andrew J. Hayes, MD, PhD
Winette T. A. van der Graaf, MD, PhD
Publication date
01-12-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 13/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07826-6

Other articles of this Issue 13/2019

Annals of Surgical Oncology 13/2019 Go to the issue